AU2022262199A1 - A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor - Google Patents
A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor Download PDFInfo
- Publication number
- AU2022262199A1 AU2022262199A1 AU2022262199A AU2022262199A AU2022262199A1 AU 2022262199 A1 AU2022262199 A1 AU 2022262199A1 AU 2022262199 A AU2022262199 A AU 2022262199A AU 2022262199 A AU2022262199 A AU 2022262199A AU 2022262199 A1 AU2022262199 A1 AU 2022262199A1
- Authority
- AU
- Australia
- Prior art keywords
- combination
- ctla4
- treatment
- itf3756
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102021000009926 | 2021-04-20 | ||
| IT102021000009926A IT202100009926A1 (it) | 2021-04-20 | 2021-04-20 | Una combinazione comprendente un inibitore di hdac6 specifico e almeno un inibitore del checkpoint ctla4 |
| PCT/EP2022/060287 WO2022223543A1 (en) | 2021-04-20 | 2022-04-19 | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022262199A1 true AU2022262199A1 (en) | 2023-09-21 |
Family
ID=76808052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022262199A Pending AU2022262199A1 (en) | 2021-04-20 | 2022-04-19 | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240207228A1 (https=) |
| EP (1) | EP4326259A1 (https=) |
| JP (1) | JP2024515100A (https=) |
| KR (1) | KR20230172001A (https=) |
| CN (1) | CN117177745A (https=) |
| AR (1) | AR125356A1 (https=) |
| AU (1) | AU2022262199A1 (https=) |
| BR (1) | BR112023021125A2 (https=) |
| CA (1) | CA3213275A1 (https=) |
| CL (1) | CL2023002894A1 (https=) |
| CO (1) | CO2023013780A2 (https=) |
| IL (1) | IL307649A (https=) |
| IT (1) | IT202100009926A1 (https=) |
| MX (1) | MX2023012030A (https=) |
| PE (1) | PE20242078A1 (https=) |
| TW (1) | TW202308609A (https=) |
| WO (1) | WO2022223543A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119424649A (zh) * | 2024-02-29 | 2025-02-14 | 中山大学附属第一医院 | 假体周围感染治疗靶点及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018008346A (es) * | 2016-01-11 | 2019-07-04 | Turnstone Lp | Terapia de combinación de virus oncológico e inhibidor de punto de control. |
| IT201700041723A1 (it) | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
-
2021
- 2021-04-20 IT IT102021000009926A patent/IT202100009926A1/it unknown
-
2022
- 2022-03-25 TW TW111111338A patent/TW202308609A/zh unknown
- 2022-04-18 AR ARP220100959A patent/AR125356A1/es unknown
- 2022-04-19 WO PCT/EP2022/060287 patent/WO2022223543A1/en not_active Ceased
- 2022-04-19 KR KR1020237039421A patent/KR20230172001A/ko active Pending
- 2022-04-19 MX MX2023012030A patent/MX2023012030A/es unknown
- 2022-04-19 EP EP22723425.9A patent/EP4326259A1/en active Pending
- 2022-04-19 PE PE2023002749A patent/PE20242078A1/es unknown
- 2022-04-19 BR BR112023021125A patent/BR112023021125A2/pt unknown
- 2022-04-19 IL IL307649A patent/IL307649A/en unknown
- 2022-04-19 CA CA3213275A patent/CA3213275A1/en active Pending
- 2022-04-19 AU AU2022262199A patent/AU2022262199A1/en active Pending
- 2022-04-19 CN CN202280027381.5A patent/CN117177745A/zh active Pending
- 2022-04-19 US US18/555,103 patent/US20240207228A1/en active Pending
- 2022-04-19 JP JP2023564130A patent/JP2024515100A/ja active Pending
-
2023
- 2023-09-28 CL CL2023002894A patent/CL2023002894A1/es unknown
- 2023-10-19 CO CONC2023/0013780A patent/CO2023013780A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021125A2 (pt) | 2023-12-12 |
| PE20242078A1 (es) | 2024-10-18 |
| EP4326259A1 (en) | 2024-02-28 |
| WO2022223543A1 (en) | 2022-10-27 |
| US20240207228A1 (en) | 2024-06-27 |
| CL2023002894A1 (es) | 2024-03-15 |
| JP2024515100A (ja) | 2024-04-04 |
| AR125356A1 (es) | 2023-07-12 |
| TW202308609A (zh) | 2023-03-01 |
| KR20230172001A (ko) | 2023-12-21 |
| IT202100009926A1 (it) | 2022-10-20 |
| IL307649A (en) | 2023-12-01 |
| CO2023013780A2 (es) | 2023-11-10 |
| CN117177745A (zh) | 2023-12-05 |
| MX2023012030A (es) | 2023-10-24 |
| CA3213275A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109069512B (zh) | 取代的氨基嘌呤化合物、其组合物以及相关治疗方法 | |
| CN115297862A (zh) | 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合 | |
| AU2017246460A1 (en) | Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| AU2019395100A1 (en) | Methods for treating castration-resistant and castration- sensitive prostate cancer | |
| EP4257609A1 (en) | Combination therapies based on pd-1 inhibitors and sik3 inhibitors | |
| US20240207228A1 (en) | A combination comprising a specific hdac6 inhibitor and at least one ctla4 checkpoint inhibitor | |
| EP4257132A1 (en) | Sik3 inhibitors for treating diseases resistant to death receptor signalling | |
| EA050310B1 (ru) | Комбинация, содержащая специфический ингибитор hdac6 и по меньшей мере одно антитело к ctla4 | |
| AU2018289354A1 (en) | Combination therapies comprising targeted therapeutics | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| RU2849370C1 (ru) | Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака | |
| JP2023516155A (ja) | ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ | |
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| CA3019391C (en) | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| US20210186978A1 (en) | Combination therapy | |
| CA3143210A1 (en) | Hsp90-binding conjugates and combination therapies thereof |